Here’s our fortnightly wrap of all the news driving ASX health stocks.
It’s been a dismal two weeks in the small cap health space, with 80 companies losing ground and just 41 advancing. Another nine were flat.
Code | Company | Price in cents | MktCap | % return since Dec 9 | % YTD return |
---|
ONT | 1300 Smiles | 680 | $ 161,013,011.20 | -4 | 16 |
1ST | 1St Group | 3.4 | $ 14,012,357.80 | -17 | -56 |
4DX | 4Dmedical | 234 | $ 386,757,475.48 | 3 | |
ACR | Acrux | 17 | $ 28,700,988.99 | -3 | -11 |
ACW | Actinogen Medical | 2 | $ 27,564,956.21 | -5 | -43 |
1AD | Adalta | 12 | $ 29,421,102.36 | -4 | 5 |
ADR | Adherium | 2.6 | $ 16,284,817.44 | -4 | -7 |
ALC | Alcidion Group | 18 | $ 188,231,869.88 | -10 | -3 |
AMT | Allegra Orthopaedics | 33.5 | $ 34,993,833.01 | -14 | 68 |
ATH | Alterity Therap | 3.4 | $ 64,990,399.30 | 0 | 70 |
AGH | Althea Group | 42 | $ 109,031,755.89 | -19 | 12 |
ATX | Amplia Therapeutics | 23.5 | $ 24,200,804.70 | 4 | 279 |
ALT | Analytica | 0.3 | $ 10,558,837.00 | 0 | 0 |
ADO | Anteotech | 10 | $ 186,960,486.10 | 10 | 364 |
ANP | Antisense Therapeut. | 13 | $ 71,748,521.38 | 35 | 44 |
APH | AP Hemp | 31.5 | $ 17,386,392.16 | -21 | 75 |
AHK | Ark Mines | 3.4 | $ 1,778,919.95 | 0 | 0 |
ARX | Aroa Biosurgery | 110 | $ 330,799,055.40 | -10 | |
AT1 | Atomo Diagnostics | 30.5 | $ 124,406,552.79 | -3 | |
AC8 | Auscann Grp Hlgs | 18 | $ 57,068,524.26 | -22 | -33 |
AHC | Austco Healthcare | 10.5 | $ 29,839,839.86 | 14 | 14 |
AVE | Avecho Biotech | 4.1 | $ 28,754,233.56 | 71 | 925 |
BD1 | Bard1 Life Sciences | 67 | $ 52,679,729.52 | -12 | -34 |
BNO | Bionomics | 15 | $ 113,963,370.25 | 15 | 104 |
BIT | Biotron | 7.9 | $ 54,048,818.90 | -4 | 52 |
BXN | Bioxyne | 1.2 | $ 7,681,744.78 | 0 | -14 |
BOT | Botanix Pharma | 12 | $ 121,642,759.25 | -11 | 46 |
BPH | BPH Energy | 3.4 | $ 20,333,158.27 | 3 | 292 |
BWX | BWX | 404 | $ 567,944,071.86 | -1 | -9 |
CAN | Cann Group | 53 | $ 148,491,957.90 | -25 | -16 |
CP1 | Cannpal Animal | 17 | $ 14,900,000.00 | -11 | 42 |
CAJ | Capitol Health | 28 | $ 287,027,932.80 | 2 | 29 |
CDX | Cardiex | 5.2 | $ 43,560,474.15 | 4 | 86 |
CDY | Cellmid | 11.5 | $ 13,199,791.82 | 15 | -48 |
CGS | Cogstate | 110 | $ 182,898,705.83 | 7 | 182 |
CMP | Compumedics | 48.5 | $ 80,609,141.34 | -1 | -39 |
CBL | Control Bionics | 100 | $ 49,560,740.00 | 1 | |
CPH | Creso Pharma | 18.5 | $ 133,953,499.23 | -38 | 48 |
CTE | Cryosite | 36 | $ 16,869,442.68 | 9 | 579 |
CYC | Cyclopharm | 250 | $ 200,686,137.50 | -4 | 113 |
CYP | Cynata Therapeutics | 68.5 | $ 81,875,946.24 | -12 | -34 |
DXB | Dimerix | 24 | $ 37,596,116.43 | -4 | 85 |
DOC | Doctor Care Anywhere | 124 | $ 220,217,562.87 | 38 | |
DVL | Dorsavi | 3.7 | $ 11,049,593.05 | 3 | 49 |
EXL | Elixinol Global | 18.5 | $ 45,798,802.51 | -36 | -62 |
FFC | Farmaforce | 9 | $ 10,945,533.30 | 6 | -10 |
GSS | Genetic Signatures | 203 | $ 242,887,068.20 | 17 | 97 |
GTG | Genetic Technologies | 0.7 | $ 66,093,813.94 | 0 | 27 |
GLH | Global Health | 43.5 | $ 18,312,769.20 | -1 | 200 |
HXL | Hexima | 17.5 | $ 21,065,171.58 | -5 | -43 |
HCT | Holista CollTech | 7.3 | $ 19,274,436.09 | 11 | -8 |
ICS | ICSGlobal | 212 | $ 22,100,439.90 | 0 | 13 |
IDT | IDT Australia | 17.5 | $ 40,515,192.88 | -22 | 25 |
IBX | Imagion Biosys | 13.5 | $ 129,096,404.97 | 8 | 478 |
IMC | Immuron | 23.25 | $ 53,306,813.91 | -1 | 79 |
IMM | Immutep | 39.5 | $ 249,051,797.61 | 41 | 52 |
IPD | Impedimed | 12 | $ 134,574,508.75 | -11 | -25 |
IMU | Imugene | 10.5 | $ 455,039,195.90 | -9 | 228 |
IHL | Incannex Healthcare | 15.5 | $ 160,181,988.99 | -6 | 150 |
ICR | Intelicare Holdings | 24.5 | $ 9,333,811.50 | -8 | |
IVX | Invion | 1 | $ 55,370,422.95 | -17 | -23 |
JHC | Japara Healthcare Lt | 61.5 | $ 167,029,580.00 | -12 | -36 |
JHL | Jayex Healthcare | 3.8 | $ 7,651,794.91 | -25 | 27 |
KZA | Kazia Therapeutics | 119 | $ 144,460,372.28 | -16 | 107 |
LBT | LBT Innovations | 12 | $ 33,248,243.86 | -14 | -25 |
LSH | Lifespot Health | 7.7 | $ 10,781,879.44 | -9 | 133 |
LCT | Living Cell Tech. | 1.6 | $ 9,143,055.70 | 14 | 0 |
M7T | Mach7 Tech | 119 | $ 279,282,349.50 | 0 | 76 |
MDR | Medadvisor | 36 | $ 134,718,788.63 | -5 | 1 |
MEB | Medibio | 0.9 | $ 12,128,963.12 | -10 | -7 |
MVP | Medical Developments | 681 | $ 463,259,914.20 | -4 | -22 |
MDC | Medlab Clinical | 24.5 | $ 69,918,917.75 | -11 | -20 |
MEM | Memphasys | 13 | $ 101,894,473.80 | 4 | 160 |
MXC | Mgc Pharmaceuticals | 2.5 | $ 45,158,055.49 | -29 | -22 |
MX1 | Micro-X | 37 | $ 125,769,613.55 | 6 | 89 |
MMJ | MMJ Group Hlds | 11.5 | $ 26,444,708.28 | -36 | -21 |
MVF | Monash IVF Group | 79 | $ 307,811,523.60 | 10 | -16 |
NC6 | Nanollose | 5.4 | $ 6,412,451.13 | 8 | 19 |
NEU | Neuren Pharmaceut. | 128.5 | $ 145,552,297.16 | -1 | -48 |
NSB | Neuroscientific | 26 | $ 23,062,786.76 | 4 | 37 |
NTI | Neurotech Intl | 3.6 | $ 18,410,377.46 | -33 | 125 |
NXS | Next Science | 128.5 | $ 157,759,682.60 | 5 | -32 |
EYE | Nova EYE Medical | 34 | $ 50,290,148.30 | 0 | -15 |
NOX | Noxopharm | 48.5 | $ 117,985,784.56 | -12 | 96 |
NYR | Nyrada Inc. | 22 | $ 16,800,249.40 | -6 | |
OSL | Oncosil Medical | 12.5 | $ 104,932,953.50 | -7 | -25 |
ONE | Oneview Healthcare | 4.5 | $ 17,663,080.32 | -12 | -58 |
OPT | Opthea | 190 | $ 641,561,921.10 | -11 | -36 |
OIL | Optiscan Imaging | 11.5 | $ 68,623,984.50 | -18 | 203 |
OCC | Orthocell | 44 | $ 75,762,652.37 | 5 | -10 |
OSP | Osprey Med Inc | 2.1 | $ 32,466,939.24 | 0 | -30 |
OSX | Osteopore | 51.5 | $ 40,189,467.00 | -3 | -29 |
OVN | Oventus Medical | 21 | $ 31,652,483.40 | -14 | -57 |
PSQ | Pacific Smiles Grp | 245 | $ 376,113,097.50 | 16 | 39 |
PCK | Painchek | 7.8 | $ 89,017,579.12 | -7 | -59 |
PAL | Palla Pharma | 78 | $ 91,942,023.21 | -2 | -26 |
PAR | Paradigm Bio. | 245 | $ 553,343,642.60 | -10 | -16 |
PGC | Paragon Care | 24.5 | $ 76,024,190.70 | 2 | -44 |
PAB | Patrys | 2.6 | $ 36,159,513.42 | 37 | 31 |
PAA | Pharmaust | 11 | $ 33,230,391.60 | -8 | 2 |
PXS | Pharmaxis | 8.4 | $ 33,363,103.03 | -7 | -48 |
PNV | Polynovo | 399 | $ 2,538,578,088.96 | 4 | 103 |
PTX | Prescient | 6.3 | $ 39,714,286.62 | -3 | 3 |
PBP | Probiotec | 229 | $ 166,756,880.10 | -3 | 18 |
PIQ | Proteomics Int Lab | 81.5 | $ 81,826,582.50 | 12 | 202 |
PYC | PYC Therapeutics | 14.5 | $ 459,784,284.94 | -3 | 136 |
RAC | Race Oncology | 176 | $ 222,510,653.75 | -18 | 826 |
RCE | Recce Pharmaceutical | 106 | $ 187,608,069.00 | -12 | 194 |
RGS | Regeneus | 12 | $ 36,034,125.72 | -8 | 38 |
RAP | Resapp Health | 8 | $ 62,923,917.59 | -11 | -67 |
RHT | Resonance Health | 21.5 | $ 98,422,265.26 | -23 | -4 |
RSH | Respiri | 13.5 | $ 93,514,302.70 | -16 | 41 |
RNO | Rhinomed | 16.5 | $ 43,147,552.44 | 6 | -21 |
RHY | Rhythm Biosciences | 81 | $ 154,144,295.42 | -1 | 612 |
SDI | SDI | 79 | $ 95,686,751.65 | -4 | -3 |
SVA | Simavita | 1.7 | $ 19,615,720.47 | 6 | -32 |
SOM | SomnoMed | 200 | $ 167,173,816.30 | -10 | -20 |
S66 | Star Combo | 31 | $ 43,107,990.08 | -14 | -36 |
SCU | Stemcell United | 1.7 | $ 13,143,716.97 | -45 | 21 |
SUD | Suda Pharmaceuticals | 3.7 | $ 14,191,160.45 | -5 | -25 |
TD1 | Tali Digital | 5 | $ 34,468,040.03 | 9 | -2 |
TLX | Telix Pharmaceutical | 384 | $ 1,087,972,649.36 | 8 | 148 |
THC | THC Global Grp | 23 | $ 46,416,952.51 | -19 | -39 |
UBI | Universal Biosensors | 46 | $ 73,670,883.83 | 7 | 142 |
VBS | Vectus Biosystems | 133 | $ 34,820,933.40 | -11 | 125 |
VTI | Vision Tech | 2.3 | $ 23,849,413.42 | -21 | -56 |
VLS | Vita Life Sciences.. | 98 | $ 53,812,198.94 | 11 | 52 |
VHT | Volpara Health Tech | 138 | $ 347,639,267.19 | 2 | -25 |
ZLD | Zelira Therapeutics | 9.3 | $ 112,605,681.77 | -7 | 69 |
ZNO | Zoono Group | 134 | $ 210,884,828.50 | -9 | 117 |
Wordpress Table Plugin
Cannabis companies were among the most volatile shares, represented among both gainers and losers.
Avecho Biotechnology (ASX:AVE) has been the biggest gainer, rising 71 per cent over the fortnight.
AVE shares, which traded around 0.8c from March through to late October, have more than tripled this month, rising as high as 4.5c on Wednesday before closing at 4.1c.
The gains came after Avecho announced yesterday it would join the CA Clinics Observational Study to test the performance of its oral cannabidiol (CBD) products.
CA Clinics hopes to enroll 3000 patients nationwide in its study. They will be surveyed via questionnaire about medicinal cannabis side effects, dosage response, and treatment satisfaction.
The data may well help cannabis products gain greater acceptance – but still, that’s a pretty dramatic share price rise for what amounts to mailing out surveys to cannabis patients.
On the flip side, medical cannabis company Stemcell United (ASX:SCU) has been the biggest loser in the 14-day period (December 9 through December 23).
Its shares spiked from around 1.4c at the start of the month to as high as 4.9c on December 9, but have been mostly in retreat since, closing Wednesday at 1.7c.
The share spike was the subject of two ASX queries.
In its first response, issued December 9, the company said it had no explanation for the recent trading in its securities.
The next day SCU asked for a trading halt and issued a $1.9 million placement at 1.9c a share – a 38.7 per cent discount off their last closing price of 3.1c – to 180 Markets Pty and CS Third Nominees.
In a follow-up letter to the ASX, issued Monday, the company said it only became aware the two parties might be interested in investing in the company the evening of December 9, when its managing director and chief executive received calls from their representatives.
“SCU believes it has promptly and without delay released the information to ASX,” the company said.
The second-biggest loser is Creso Pharma (ASX:CPH), although it was coming off a stellar run in the first part of the month.
CPH shares are down 38 per cent for the fortnight, but are still up by 311 per cent so far for the month.
Another cannabis company, Elixinol Global (ASX:EXL), was the third-biggest loser, dropping 36 per cent.
At Stockhead we tell it like it is. While Creso Pharma is a Stockhead advertiser, they did not sponsor this article.
You might be interested in